EPAC1 inhibition protects the heart from doxorubicin-induced toxicity

Anthracyclines, such as doxorubicin (Dox), are widely used chemotherapeutic agents for the treatment of solid tumors and hematologic malignancies. However, they frequently induce cardiotoxicity leading to dilated cardiomyopathy and heart failure. This study sought to investigate the role of the exch...

Full description

Bibliographic Details
Published in:eLife
Main Authors: Marianne Mazevet, Anissa Belhadef, Maxance Ribeiro, Delphine Dayde, Anna Llach, Marion Laudette, Tiphaine Belleville, Philippe Mateo, Mélanie Gressette, Florence Lefebvre, Ju Chen, Christilla Bachelot-Loza, Catherine Rucker-Martin, Frank Lezoualch, Bertrand Crozatier, Jean-Pierre Benitah, Marie-Catherine Vozenin, Rodolphe Fischmeister, Ana-Maria Gomez, Christophe Lemaire, Eric Morel
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2023-08-01
Subjects:
doxorubicin
cardiotoxicity
EPAC1
cardiology
Online Access:https://elifesciences.org/articles/83831

Internet

https://elifesciences.org/articles/83831

Similar Items